Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Wojciech Jurczak"'
Autor:
Pier Luigi Zinzani, Marek Trněný, Vincent Ribrag, Vittorio Ruggero Zilioli, Jan Walewski, Jacob Haaber Christensen, Vincent Delwail, Guillermo Rodriguez, Parameswaran Venugopal, Morton Coleman, Caroline Dartigeas, Caterina Patti, Fabrizio Pane, Wojciech Jurczak, Michal Taszner, Shankara Paneesha, Fred Zheng, Douglas J. DeMarini, Wei Jiang, Aidan Gilmartin, Amitkumar Mehta
Publikováno v:
EClinicalMedicine, Vol 62, Iss , Pp 102131- (2023)
Summary: Background: Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit in patients with relapsed/refractory (R/R) B-cell malignancies. In this phase 2 study (CITADEL-205; NCT03235544, EudraCT 2017-003148-19
Externí odkaz:
https://doaj.org/article/2eed59c08fdd45b896bddf048a659297
Autor:
Brendan P. Hodkinson, Michael Schaffer, Joshua D. Brody, Wojciech Jurczak, Cecilia Carpio, Dina Ben-Yehuda, Irit Avivi, Ann Forslund, Muhit Özcan, John Alvarez, Rob Ceulemans, Nele Fourneau, Anas Younes, Sriram Balasubramanian
Publikováno v:
Translational Oncology, Vol 14, Iss 1, Pp 100977- (2021)
We analyzed potential biomarkers of response to ibrutinib plus nivolumab in biopsies from patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter's transformation (RT) from the LYM1002 phase I/IIa study, using progr
Externí odkaz:
https://doaj.org/article/91087acb7391463aae85c4eba847cc09